We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$588M
AUM Growth
+$7.2M
Cap. Flow
-$2.16M
Cap. Flow %
-0.37%
Top 10 Hldgs %
36.51%
Holding
220
New
75
Increased
41
Reduced
27
Closed
76

Top Buys

1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.57M
2
UTHR icon
United Therapeutics
UTHR
+$8.62M
3
INCY icon
Incyte
INCY
+$7.79M
4
COGT icon
Cogent Biosciences
COGT
+$7.05M
5
VKTX icon
Viking Therapeutics
VKTX
+$6.05M

Top Sells

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.95M
2
TERN
Terns Pharmaceuticals
TERN
+$6.74M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$4.21M
4
BIOA
BioAge Labs
BIOA
+$4.07M
5
CORT icon
Corcept Therapeutics
CORT
+$3.27M

Sector Composition

1 Healthcare 38.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
201
Stoke Therapeutics
STOK
$1.81B
– –
-17,181
Closed -$545K
TERN
202
CALL
DELISTED
Terns Pharmaceuticals
TERN
– –
-64,700
Closed -$2.61M
TGTX icon
203
PUT
TG Therapeutics
TGTX
$8.4B
– –
-100,000
Closed -$2.98M
TVTX icon
204
PUT
Travere Therapeutics
TVTX
$5.27B
– –
-50,300
Closed -$1.92M
VIR icon
205
Vir Biotechnology
VIR
$1.59B
– –
-100,000
Closed -$797K
VKTX icon
206
PUT
Viking Therapeutics
VKTX
$4.31B
– –
-316,700
Closed -$11.1M
VNDA icon
207
CALL
Vanda Pharmaceuticals
VNDA
$327M
– –
-200,000
Closed -$1.76M
VRDN icon
208
Viridian Therapeutics
VRDN
$1.99B
– –
-21,114
Closed -$657K
VTGN icon
209
CALL
VistaGen Therapeutics
VTGN
$9.4M
– –
-106,500
Closed -$70.5K
VTYX
210
DELISTED
Ventyx Biosciences
VTYX
– –
-200,000
Closed -$1.81M
XBI icon
211
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-250,000
Closed -$30.5M
ZYME icon
212
CALL
Zymeworks
ZYME
$1.78B
– –
-240,600
Closed -$6.33M
ZYME icon
213
PUT
Zymeworks
ZYME
$1.78B
– –
-21,400
Closed -$563K
BIOA
214
CALL
BioAge Labs
BIOA
$1.01B
– –
-22,600
Closed -$299K
TECX
215
CALL
Tectonic Therapeutic
TECX
$615M
– –
-100,600
Closed -$2.1M
NEUP
216
Neuphoria Therapeutics
NEUP
$18.5M
– –
-50,000
Closed -$194K
ONC
217
BeOne Medicines Ltd
ONC
$32.4B
– –
-7,500
Closed -$173K
AARD
218
Aardvark Therapeutics
AARD
$128M
– –
-15,882
Closed -$208K
MPLT
219
MapLight Therapeutics
MPLT
$1.72B
– –
-63,791
Closed -$1.12M
5 6 7 8
9

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
BCM
Blume Capital Management Berkeley, California $588M AUM 29.16% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
BMWS
Brady Martz Wealth Solutions Grand Forks, North Dakota $587M AUM 17.88% 1-Year Est. Return
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return

Diadema Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Diadema Partners held 220 positions worth $588M, up 1.2% from $581M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners's Q1 2026 filing shows 75 new, 41 increased, 27 reduced and 76 closed positions. Its largest new stake was Jazz Pharmaceuticals: 54,755 shares worth $10.4M. The largest sale was Regeneron Pharmaceuticals, an estimated $7.95M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 29% a quarter earlier.

  • Diadema Partners's largest Q1 2026 buy was Jazz Pharmaceuticals: 54,755 shares worth $10.4M.
  • Diadema Partners added most to United Therapeutics in Q1 2026, an estimated $8.62M increase.
  • Diadema Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $6.74M.
  • Diadema Partners fully exited Regeneron Pharmaceuticals in Q1 2026, selling an estimated $7.95M.
  • Diadema Partners's ten largest holdings make up 37% of its $588M portfolio in Q1 2026.
  • Diadema Partners opened 75 new positions and closed 76 in Q1 2026.
  • Diadema Partners's portfolio value rose 1.2% quarter-over-quarter to $588M.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.